Let Me Tell You a Story About the Power of Medical Research
Ten-year-old Michael Methner told his story about his experience being diagnosed with optic nerve glioma at the Rally for...
Category: Policy
Ten-year-old Michael Methner told his story about his experience being diagnosed with optic nerve glioma at the Rally for...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Expanding clinical trial eligibility requirements can help increase participation and more accurately show how treatments work in a real-world...
Highlights from a workshop and journal article that shared key considerations for including overall survival as an endpoint in...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
Dr. Edward Cliff presented a poster on the clinical benefit of cancer drugs granted accelerated approval.
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
In the beginning of his cancer journey, Edward Cutler felt unlucky. In 2012, he saw an ad suggesting that...
FDA approvals issued in third quarter 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new...